Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022

Welcome to OncLive On Air^®! I’m your host today, Ashling Wahner.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Novartis, we feature interviews highlighting updates in the treatment of patients with hormone receptor (HR)–positive breast cancer that were presented at the 2022 San Antonio Breast Cancer Symposium.

Yen-Shun Lu, MD, PhD, the division chief of Medical Oncology in the Department of Oncology at National Taiwan University Hospital in Taipei, discussed the primary results from the phase 2 RIGHT Choice trial (NCT03839823), which investigated ribociclib (Kisqali) plus endocrine therapy in premenopausal patients with aggressive HR-positive, HER2-negative breast cancer.

Patrick Neven, MD, PhD, a gynecologist and oncologist at University Hospitals Leuven in Belgium, shared findings from the pooled analysis of post-progression treatments after first-line ribociclib and endocrine therapy in HR-positive, HER2-negative advanced breast cancer in the phase 3 MONALEESA-2 (NCT01958021), MONALEESA-3 (NCT02422615), and MONALEESA-7 (NCT02278120) trials.

William Jacot, MD, PhD, a professor of oncology at the University of Montpellier in France, walked through the primary efficacy and safety results from the phase 2 AMALEE trial (NCT03822468), which evaluated first-line ribociclib starting doses of 400 mg and 600 mg in HR-positive, HER2-negative advanced breast cancer.

Arielle Medford, MD, a clinical fellow in medicine at Dana-Farber Cancer Institute in Boston, Massachusetts, discussed cell-free DNA monitoring in the phase 2 LEADER trial (NCT03285412), which is evaluating adjuvant endocrine therapy plus ribociclib in localized HR-positive, HER2-negative breast cancer.

Laura Spring, MD, a clinical and translational investigator at Massachusetts General Hospital Cancer Center and Harvard Medical School, both in Boston, explained results from an analysis of the phase 3 RxPONDER trial (NCT01272037) that evaluated the effect of HER2 low status on clinical outcomes in patients with HR-positive, HER2-negative breast cancer who received endocrine therapy with or without chemotherapy.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®, sponsored by Novartis. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.